6 min read

Amyloid PET Scan vs. Blood Test for Alzheimer's: Cost, Accuracy, and Coverage

Compare amyloid PET scans, p-tau217 blood tests, and CSF lumbar punctures for Alzheimer's: Medicare coverage, wait times, costs, and clinical trial options.

By Tokei Health, Cognitive Health Editorial Team

Free 3-Minute Online Check · Instant Score

Draw the 11:10 clock on screen or upload a photo of a paper sheet — no signup required.

Start Free Screen & Trial Check

When memory changes prompt a deeper workup, families quickly run into three different ways to look for Alzheimer's biology: a blood biomarker test (such as p-tau217), an amyloid PET brain scan, or a cerebrospinal fluid (CSF) lumbar puncture.

All three aim to answer the same core question—whether beta-amyloid plaques have built up in the brain—but they differ dramatically in cost, wait times, invasiveness, and insurance rules. Knowing how they fit together helps you understand why doctors usually follow a step-by-step sequence instead of jumping straight to the most expensive scan.

What Each Biomarker Test Actually Detects

1. Amyloid PET Scan (Direct Brain Imaging)

An amyloid PET scan uses a small intravenous injection of an FDA-approved radioactive tracer (such as florbetapir, florbetaben, or flutemetamol) that binds directly to beta-amyloid plaques in the brain. After an uptake period of roughly 45 to 90 minutes, a PET scanner creates a 3D map showing both whether plaques are present and where in the cortex they have accumulated.

2. Blood Biomarker Test (Plasma p-tau217)

A standard venous blood draw measures tiny amounts of Alzheimer's-related proteins—most notably phosphorylated tau 217 (p-tau217), sometimes paired with the Aβ42/40 ratio—that enter the bloodstream as amyloid plaques trigger tau changes in neurons. It does not produce an image of the brain, but high-precision assays predict amyloid PET positivity with roughly 90% to 95% accuracy when results fall outside the intermediate zone.

3. CSF Lumbar Puncture (Spinal Tap)

A specialist collects a small sample of cerebrospinal fluid from the lower back (below where the spinal cord ends). Because CSF directly bathes the brain, it provides highly accurate measurements of Aβ42/40, p-tau181, and total tau, and can also screen for non-Alzheimer's causes of cognitive decline (such as autoimmune, infectious, or inflammatory conditions) in a single procedure.

Side-by-Side Comparison: PET vs. Blood Test vs. CSF

| Factor | Amyloid PET Scan | Blood Test (p-tau217) | CSF Lumbar Puncture | | :--- | :--- | :--- | :--- | | What It Measures | Direct 3D visualization of brain beta-amyloid plaques | Blood levels of p-tau217 (and optionally Aβ42/40) | Direct brain-fluid levels of Aβ42/40, p-tau, and total tau | | Invasiveness & Comfort | IV tracer injection + lying still in scanner (20–30 min scan; 1.5–2 hrs total visit); low-dose radiation | Simple 5-minute blood draw; no radiation | Outpatient lower-back needle procedure (30–45 min); small risk of temporary post-procedure headache | | Typical Wait Time | Often 4 to 12+ weeks depending on local PET scanner and radiotracer availability | Days to 2 weeks (draw at local clinic or reference lab) | 2 to 6 weeks to schedule with neurology or interventional radiology | | Uninsured / Cash Cost | Roughly $3,000 – $7,000+ | Roughly $200 – $1,450 depending on standalone vs. multi-marker panel | Roughly $1,000 – $2,500 (procedure + lab analysis) | | Medicare Coverage Landscape | Covered via regional MACs when medically necessary (post-2023 CMS update); Part B coinsurance applies | Evolving and assay-dependent; out-of-pocket or lab assistance still common | Generally covered by Medicare when medically necessary for cognitive evaluation | | Best Clinical Role | Confirmatory gold standard, treatment initiation, and resolving indeterminate blood results | Fast, scalable first-line triage after cognitive screening | Cost-effective gold-standard confirmation, especially in younger-onset or atypical cases |

How Medicare Coverage for Amyloid PET Changed

For roughly a decade, Medicare enforced a strict National Coverage Determination (NCD) that refused to pay for amyloid PET scans outside of approved clinical trials—and even then limited beneficiaries to one scan per lifetime. That rule was written in an era when no disease-modifying Alzheimer's treatments were approved.

In October 2023, the Centers for Medicare & Medicaid Services (CMS) retired that national restriction. Today:

  • Regional Medicare Administrative Contractors (MACs) determine coverage based on medical necessity—typically for patients with documented mild cognitive impairment (MCI) or mild dementia where confirming amyloid status will directly guide care (such as evaluating eligibility for anti-amyloid therapy).
  • Multiple scans are no longer barred nationally, which matters for patients on therapies where clinicians may need to verify plaque clearance over time.
  • Out-of-pocket costs still apply: Under Original Medicare Part B, beneficiaries without supplemental (Medigap) insurance may still owe the standard 20% coinsurance—which on a $4,000 scan can mean $800 out of pocket. Medicare Advantage plans often require prior authorization.

Why Doctors Usually Start With Cognitive Screening + a Blood Test

Even with improved Medicare coverage, amyloid PET scans remain a bottleneck. Many rural and suburban hospitals do not have access to amyloid radiotracers, and urban academic centers often have multi-month waiting lists.

Because of those real-world constraints, modern memory clinics increasingly use a stepped triage pathway:

  1. Step 1 — Reversible causes & cognitive baseline: Basic bloodwork (B12, TSH, metabolic panel), a medication review, structural brain MRI (to check for strokes, tumors, or fluid buildup), and objective cognitive screening. Before your appointment, you can document a baseline using our printable Clock Drawing Test or review existing screening scores in the cognitive score interpreter.
  2. Step 2 — Plasma p-tau217 blood test: Fast, low-burden biological triage.
    • If the blood test is clearly negative, a PET scan is often unnecessary, saving months of waiting and thousands of dollars while pivoting the workup to vascular, sleep, or metabolic factors.
    • If the blood test is clearly positive, it accelerates specialist referral and care planning.
  3. Step 3 — Confirmatory PET or CSF (when needed): Reserved for intermediate (gray-zone) blood results, complex or atypical presentations, or when formal confirmation is required prior to starting an anti-amyloid infusion.

How Clinical Trials Cover PET and Biomarker Testing at No Cost

One option many families overlook is clinical research. Because modern Alzheimer's prevention and early-stage treatment trials require confirmed biomarker status, study sponsors routinely fund the entire diagnostic workup for eligible volunteers, including:

  • Standardized plasma p-tau217 and genetic screening
  • Amyloid PET and/or tau PET brain scans
  • High-resolution structural brain MRIs
  • Longitudinal cognitive testing with memory specialists

For adults experiencing mild memory changes—or cognitively healthy adults with a strong family history who would not qualify for Medicare-covered PET scans clinically—participating in a clinical trial can provide access to gold-standard biomarker imaging at zero out-of-pocket cost while contributing to new therapies.

If you want to take a brief, objective cognitive self-check and explore trial-oriented next steps, you can start the Tokei Health cognitive self-check for clinical trials.

Questions to Ask Before Scheduling a Scan or Blood Test

  • "Will the result of this test change our treatment plan, specialist referral, or clinical trial options?"
  • "Can we start with a p-tau217 blood test before waiting months for an amyloid PET scan?"
  • "If we order an amyloid PET scan, has prior authorization been submitted and what is my estimated coinsurance?"
  • "Have we already ruled out reversible causes like sleep apnea, hearing loss, B12/thyroid issues, or sedating medications?"

If you are already taking prescription medications for memory, blood pressure, or mood, never discontinue them abruptly while awaiting test results—always review any changes with your prescribing physician.

Educational notice: Tokei Health (Coadia, Inc.) provides educational cognitive self-check software and informational resources. It is not a healthcare provider and does not provide medical advice, diagnosis, or treatment.

Frequently Asked Questions

Is a p-tau217 blood test accurate enough to replace an amyloid PET scan?
In many clear-cut cases, a high-performing p-tau217 blood test can rule amyloid pathology in or out with roughly 90% to 95% accuracy. However, if the blood result falls in the intermediate gray zone—or if a patient is being evaluated for anti-amyloid infusion therapy—many specialists still confirm with an amyloid PET scan or CSF test.
Does Medicare cover amyloid PET scans for Alzheimer's now?
Yes. In October 2023, the Centers for Medicare & Medicaid Services (CMS) removed its long-standing national restriction that limited amyloid PET scans to one scan per lifetime inside clinical trials. Coverage decisions are now handled by regional Medicare Administrative Contractors (MACs) when medically necessary.
How much does an amyloid PET scan cost out of pocket?
Without insurance coverage, an amyloid PET scan typically costs between $3,000 and $7,000 or more, depending on the imaging facility, radiotracer, and geographic region. With Medicare or commercial coverage, patients are generally responsible for standard deductibles and coinsurance (such as 20% under Medicare Part B unless covered by Medigap).
Why would a doctor order a spinal tap (CSF test) instead of an amyloid PET scan?
A lumbar puncture (CSF test) is typically far less expensive than a PET scan, involves no radiation exposure, and can measure multiple proteins at once—including amyloid, tau, and markers of other neurological conditions—making it useful when the clinical picture is complex.
Do Alzheimer's clinical trials pay for amyloid PET scans?
Yes. Most Phase 2 and Phase 3 Alzheimer's clinical trials cover the full cost of required biomarker screening—including blood tests, amyloid or tau PET scans, and brain MRIs—at no cost to qualifying participants.
Educational Self-Check

Take a 3-Minute Cognitive Baseline & Check Study Eligibility

Start with our free 3-minute clock & delayed recall screen, check reversible medication and sleep contributors, and optionally match with enrolling MCI and Alzheimer's studies near your ZIP code.

Start Free Screen & Trial Check

Free 3-minute clock check · No account required

Educational self-check software: Tokei Health (Coadia, Inc.) is not a healthcare provider and does not offer medical services, diagnosis, or medical advice. Always consult a qualified physician or pharmacist before making any health or medication decisions.